Background In a phase 1 trial, axicabtagene ciloleucel (axi-cel), an autologous anti-CD19
chimeric antigen receptor (CAR) T-cell therapy, showed efficacy in patients with refractory …

Background Axicabtagene ciloleucel is an autologous anti-CD19 chimeric antigen receptor (CAR)
T-cell therapy. In the previous analysis of the ZUMA-1 registrational study, with a …

Background Diffuse large B-cell lymphomas (DLBCLs) are phenotypically and genetically
heterogeneous. Gene-expression profiling has identified subgroups of DLBCL (activated B-cell…

Background Chronic lymphocytic leukemia (CLL) primarily affects older persons who often
have coexisting conditions in addition to disease-related immunosuppression and …

Background Hodgkin's lymphoma and anaplastic large-cell lymphoma are the two most
common tumors expressing CD30. Previous attempts to target the CD30 antigen with …

Purpose Brentuximab vedotin is an antibody-drug conjugate (ADC) that selectively delivers
monomethyl auristatin E, an antimicrotubule agent, into CD30-expressing cells. In phase I …

PURPOSE: Radioimmunotherapy combines biologic and radiolytic mechanisms to target
and destroy tumor cells, thus offering a needed therapeutic alternative for refractory non-…

Purpose Systemic anaplastic large-cell lymphoma (ALCL) is an aggressive subtype of T-cell
lymphoma characterized by the uniform expression of CD30. The antibody-drug conjugate …

Background The Hu5F9-G4 (hereafter, 5F9) antibody is a macrophage immune checkpoint
inhibitor blocking CD47 that induces tumor-cell phagocytosis. 5F9 synergizes with rituximab …

Background Ibrutinib has been approved by the Food and Drug Administration for the
treatment of patients with untreated chronic lymphocytic leukemia (CLL) since 2016 but has not …